Medistim

Earnings Release • Aug 31, 2023

SECOND QUARTER AND FIRST HALF FINANCIAL RESULTS 2023 FOR MEDISTIM ASA

SECOND QUARTER AND FIRST HALF FINANCIAL RESULTS 2023 FOR MEDISTIM ASA

Sales for the second quarter ended at MNOK 137.4 (MNOK 117.5), an increase of 16.9%. Sales for first half ended at MNOK 266.6 (MNOK 233.6), an increase of 14.1%.

Currency neutral sales of own products was up 4.0% for the quarter and 2.5% for the first half.

Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an EBIT margin at 30.7% (MNOK 37.3 an EBIT margin at 31.8%). For the first half EBIT is up 6.9% and ended at MNOK 75.7 an EBIT margin at 32.6% for the first half (MNOK 70.8 an EBIT margin at 35.3%).

Medistim established direct sales organizations in both Canada and China in Q2 and continues to strengthen its organization worldwide.

Medistim announced its participation in a groundbreaking cardiac surgery trial dedicated to women, ROMA-W.

A dividend of NOK 4.50 per share, a total of MNOK 82.2, was paid 5th of May.